Is Dynavax Technologies Corp. overvalued or undervalued?

As of 6 May 2025, the valuation grade for Dynavax Technologies Corp. has moved from expensive to risky, indicating a shift in investor sentiment. The company appears to be overvalued at this time. Key ratios include a P/E ratio of 54, a price-to-book value of 2.32, and an EV to EBITDA ratio of -832.88, which highlights significant concerns regarding profitability and valuation metrics.
In comparison to its peers, Dynavax's P/E ratio of 54 is higher than Prothena Corp. Plc's P/E of -2.78, while its PEG ratio of 0.58 suggests potential growth at a reasonable price, though this is overshadowed by negative earnings metrics. The company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -23.49% compared to the index's 2.44%, reinforcing the notion that Dynavax may not be a favorable investment at its current valuation.